Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calibra Receives 510(k) Clearance For Finesse Insulin Patch-Pen
Measuring roughly 2” long, 1” wide and ¼” thick, Finesse is a small plastic device designed to adhere to a patient’s skin. Finesse is able to hold and
Measuring roughly 2” long, 1” wide and ¼” thick, Finesse is a small plastic device designed to adhere to a patient’s skin. Finesse is able to hold and
The company claims that Virsani kills viruses, bacteria, and other pathogens on hands and surfaces and is available in a small aerosol can suitable for mobile personal hygiene.
Raghav Chari, senior vice president of proprietary products business at Dr Reddy’s, said: “We are extremely pleased to be working with Aegis and gaining access to their patented
AMT has concluded two clinical studies for LPLD in Europe and Canada. Long term follow-up from both of these is ongoing, as is a third clinical study in
The presentations delivered by Robbert de Winter of the Academic Medical Center (AMC) in Amsterdam, and Wojciech Wojakowski from Medical University of Silesia in Poland, focused on the
The company said that the process developers can use the tool to determine which filters are needed to produce a desired volume of monoclonals. The tool features an
rFIXFc is a fully-recombinant clotting factor developed using Biogen Idec’s proprietary monomeric Fc-fusion technology. In the B-Long trial, rFIXFc’s ability to prevent bleeding using different dosing regimens will
However, no safety concerns were raised. As a result of the DSMB findings and recommendation, the company has decided to discontinue the study. Liplong is a randomized, double-blind
Jim Jersey, president and CEO at Agilux, said: “In launching the LC/MS/MS GLP bioanalytical services, we have challenged ourselves to be as innovative as we were in discovery,
Actavis has launched the product under its own brand name on day one in the UK and France, where the patents expired on 20 and 21 January, respectively.